Your browser doesn't support javascript.
loading
Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients.
Barbanti, Piero; Aurilia, Cinzia; Egeo, Gabriella; Fofi, Luisa; Guadagni, Fiorella; Ferroni, Patrizia.
Afiliação
  • Barbanti P; Headache and Pain Unit, 46729IRCCS San Raffaele Pisana, Rome, Italy.
  • Aurilia C; Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, Rome, Italy.
  • Egeo G; Headache and Pain Unit, 46729IRCCS San Raffaele Pisana, Rome, Italy.
  • Fofi L; Headache and Pain Unit, 46729IRCCS San Raffaele Pisana, Rome, Italy.
  • Guadagni F; Headache and Pain Unit, 46729IRCCS San Raffaele Pisana, Rome, Italy.
  • Ferroni P; Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, Rome, Italy.
Cephalalgia ; 40(11): 1168-1176, 2020 10.
Article em En | MEDLINE | ID: mdl-32484361
ABSTRACT

BACKGROUND:

Dopaminergic symptoms may be extremely pronounced in some migraine patients during the attack, representing a major source of disability.

OBJECTIVES:

We aimed to carefully characterize the clinical picture of migraine patients with dopaminergic symptoms in a large patients' population as a putative migraine endophenotype, allowing more precise disease management, treatment and outcome prediction.

METHODS:

We screened 1148 consecutive tertiary care episodic and chronic migraine patients with face-to-face interviews collecting thorough data on lifestyle, socio-demographic factors, and clinical migraine features.

RESULTS:

We identified 374 patients with migraine with dopaminergic symptoms (32.6%). The most frequent dopaminergic symptom was yawning followed by somnolence, nausea, vomiting, fatigue, mood changes and diuresis. Migraine patients with dopaminergic symptoms had longer attack duration (OR 1.82; 95% CI 1.41-2.36, p < 0.0001), more frequent osmophobia (OR 2.01; 95% CI 1.50-2.69, p < 0.0001), allodynia (OR 1.43; 95% CI 1.10-1.85, p = 0.0071) and unilateral cranial autonomic symptoms (OR 1.31; 95% CI 1.01-1.68, p = 0.045), but used less preventative treatments (OR 0.74; 95% CI 0.57-0.98, p = 0.033) than patients without dopaminergic symptoms.

CONCLUSIONS:

Migraine patients with dopaminergic symptoms are characterized by a full-blown, more disabling migraine. Dopaminergic system modulation should be carefully considered in individuals with migraine with dopaminergic symptoms for both acute and preventative treatments in future ad hoc designed studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos de Enxaqueca Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos de Enxaqueca Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article